Boneplex Tablet
Boneplex Tablet, licence 80141428: inactive licence in Health Canada data. The French and European references below do not constitute authorisation for sale in France or an assessment of safety or efficacy.
Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.
Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)
Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)
Natural health product licensed in Canada
- Licence holder
- Viva Pharmaceutical Inc.
- NPN or DIN-HM
- 80141428
- Status
- Inactive licence
- Licence date
- 2 June 2025
- Revision date
- Not provided
- Form
- Comprimé
- Route of administration
- Orale
- Application type
- Générale (non traditionelle)
If this product were sold in France
No point flagged by the rules we apply.
A daily quantity is calculated only for an explicit adult oral dosage, stated per day and in a solid unit matching the product form. Ambiguous units, liquids, powders and paediatric doses are not extrapolated. A quantity not calculated is not compared with dose limits. This analysis does not constitute authorisation for sale in France or an assessment of safety or efficacy.
Composition
| Medicinal ingredient and source | Per dosage unit, according to the source | Maximum per day, adult |
|---|---|---|
| Bore Source : Boron hydrolyzed vegetable protein (HVP) chelate | 700.0 Microgrammes | Not calculated |
| Calcium Source : Carbonate de calcium | 500.0 mg | 500,000 µg |
| Tamarindus indica Extract : Matériel brut sec Extraction ratio : 5:1 Dry plant equivalent : 835 mg | 167.0 mg | Not calculated |
| Curcuma longa Source : Curcuma longa - rhizome Extract : Matériel brut sec Extraction ratio : 10:1 Dry plant equivalent : 830 mg Potency : 35.0 % Curcumin | 83.0 mg | Not calculated |
| Boswellia serrata Potency : 40.0 % Boswellic acids | 30.0 mg | Not calculated |
| Harpagophytum procumbens Source : Harpagophytum procumbens - Secondary root tuber Extract : Matériel brut sec Extraction ratio : 8:1 Dry plant equivalent : 200 mg | 25.0 mg | Not calculated |
| Collagène hydrolysé Source : Bovin - peau | 30.0 mg | Not calculated |
| Vitamine D Source : Cholécalciférol | 200.0 UI | 5 µg |
| Vitamine D Source : Cholécalciférol | 5.0 Microgrammes | Not calculated |
Non-medicinal ingredients
Stéarate de magnésium, Talc, Dioxyde de titane, Cellulose microcristalline, Eau purifiée, Croscarmellose de sodium, Poly(éthylène glycol), Poly(alcool vinylique), Dioxyde de silicium, Hypromellose
Recommended doses in Canada
| Population | Age | Quantity per serving | Frequency |
|---|---|---|---|
| Adultes | minimum: 19.0 ans | 1.0 Comprimé | 1.0 Jour(s) |
Uses authorised in Canada
Text supplied in English because no French text is available.
Recommended use or purpose Source of antioxidants/Provides antioxidants. As part of a healthy diet (when taken with Vitamin D) may help prevent bone loss/osteoporosis. Helps to build strong bones/(and) teeth. Source of (an) antioxidant(s)/Provides (an) antioxidant(s).
A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.
Warnings in Canada
No French warning text available in the imported data.
Source
Official Health Canada record, licence 80141428
The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.
The evidence date of this ingredient list is unknown.
Has the product changed? Photograph the packaging.